Moderna invests USD140M to expand US manufacturing capabilities at Massachusetts facility

USA—Moderna has committed USD140 million to expand its onshore manufacturing facilities, bringing complete drug product manufacturing capabilities to its Norwood, Massachusetts Moderna Technology Center (MTC).

This investment strengthens the company’s U.S.-based production infrastructure and marks a significant step toward self-sufficiency in pharmaceutical manufacturing.

Stéphane Bancel, Moderna’s chief executive officer, emphasized the importance of this development.

By bringing drug product manufacturing in-house at the Norwood campus, the company has completed the full manufacturing loop under one roof in the United States.

As an American company, Moderna remains committed to building and producing domestically while creating meaningful employment opportunities for the local community.

Construction at the MTC is currently underway and is scheduled for completion during the first half of 2027.

Reuters reports that the expansion project will generate hundreds of skilled biomanufacturing jobs in the area.

Previously, Moderna relied on external partners to handle the fill-finish stage of drug product manufacturing.

This arrangement created potential challenges related to costs, timing, and operational efficiency.

The new investment eliminates these dependencies by giving Moderna complete control over the entire production process, from start to finish.

The MTC expansion demonstrates Moderna’s ongoing commitment to strengthening its U.S.-based infrastructure.

The enhanced facility will support the company’s pipeline of mRNA vaccines and therapeutics while improving connections throughout its domestic manufacturing network.

Moderna first announced plans for the MTC in September 2016, envisioning a state-of-the-art clinical manufacturing facility for messenger RNA-based drugs and vaccines.

The company completed the initial building construction in early 2018 with a US$110 million investment, creating more than 200 jobs.

The facility produces various mRNA products for good laboratory practice toxicology studies and Phase I and II clinical trials, including Covid-19 vaccines.

The site features integrated end-to-end process facilities with spaces for good manufacturing practice manufacturing, plasmid production, pre-clinical operations, quality control laboratories, development labs, and a cancer vaccine unit.

It also includes warehouse space, maintenance facilities, and administrative offices.

The MTC handles all manufacturing activities from raw material production to active pharmaceutical ingredients, formulation, and now filling and finishing.

The facility produces up to 40 batches of GMP mRNA annually.

Beyond manufacturing, the building houses all quality and infrastructure services.

 It features a collaborative open-plan office design with modern amenities and hosts Moderna’s personalized cancer vaccine unit, which produces individual supply batches of mRNA for cancer vaccines.

The International Society for Pharmaceutical Engineering recognized the facility’s innovative capabilities in 2019 with its Facility of the Future award.